Verrica says pooled Phase 3 analysis shows YCANTH clears molluscum about 4x faster than vehicle

Bitget2026/09/30 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Verrica set poster presentations for October at two dermatology meetings, featuring a new pooled analysis of Phase 3 YCANTH trials.
Results have not been presented yet; the analysis is scheduled for the Fall Clinical Dermatology Conference on October 8-11, 2026.
The study found YCANTH cleared molluscum contagiosum faster than vehicle, with consistent benefits regardless of how long patients had disease.
An encore poster will also reprise previously presented Phase 2 VP-315 data, exploring signs of activity in untreated basal cell carcinoma lesions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300800PRIMZONEFULLFEED9836639) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Verrica says pooled Phase 3 analysis shows YCANTH clears molluscum about 4x faster than vehicle

You may also like

Crypto prices